Terms: = Breast cancer AND TNFRSF17, BCMA, 608, ENSG00000048462, CD269, Q02223, BCM
319 results:
1. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial.
Fehm T; Cottone F; Dunton K; André F; Krop I; Park YH; De Laurentiis M; Miyoshi Y; Armstrong A; Borrego MR; Yerushalmi R; Duhoux FP; Takano T; Lu W; Egorov A; Kim SB
Lancet Oncol; 2024 May; 25(5):614-625. PubMed ID: 38697155
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
Roussot N; Constantin G; Desmoulins I; Bergeron A; Arnould L; Beltjens F; Mayeur D; Kaderbhai C; Hennequin A; Jankowski C; Padeano MM; Costaz H; Jacinto S; Michel E; Amet A; Coutant C; Costa B; Jouannaud C; Deblock M; Levy C; Ferrero JM; Kerbrat P; Brain E; Mouret-Reynier MA; Coudert B; Bertaut A; Ladoire S
Eur J Cancer; 2024 May; 202():114037. PubMed ID: 38554542
[TBL] [Abstract] [Full Text] [Related]
3. Digital pathology for reporting histopathology samples, including cancer screening samples - definitive evidence from a multisite study.
Azam AS; Tsang YW; Thirlwall J; Kimani PK; Sah S; Gopalakrishnan K; Boyd C; Loughrey MB; Kelly PJ; Boyle DP; Salto-Tellez M; Clark D; Ellis IO; Ilyas M; Rakha E; Bickers A; Roberts ISD; Soares MF; Neil DAH; Takyi A; Raveendran S; Hero E; Evans H; Osman R; Fatima K; Hughes RW; McIntosh SA; Moran GW; Ortiz-Fernandez-Sordo J; Rajpoot NM; Storey B; Ahmed I; Dunn JA; Hiller L; Snead DRJ
Histopathology; 2024 Apr; 84(5):847-862. PubMed ID: 38233108
[TBL] [Abstract] [Full Text] [Related]
4. Evaluation of complexity and deliverability of IMRT treatment plans for breast cancer.
Duan L; Qi W; Chen Y; Cao L; Chen J; Zhang Y; Xu C
Sci Rep; 2023 Dec; 13(1):21474. PubMed ID: 38052915
[TBL] [Abstract] [Full Text] [Related]
5. Treatment of Internal Mammary Nodes is Associated With Improved Overall Survival in breast cancer: A Meta-Analysis.
Shaikh PM; Mulherkar R; Khasawneh MT; Clump D; Hazard-Jenkins H; Hafez M; Vargo JA
Am J Clin Oncol; 2024 Feb; 47(2):81-87. PubMed ID: 37916961
[TBL] [Abstract] [Full Text] [Related]
6. [Antibody drug conjugates (ADC) and bispecific antibodies in oncology - report of the 2022 Saint Louis day].
Ranchon F; Chatelut É; Lambert J; Sesques P; Thibault C; Madelaine I; Rioufol C; Diéras V; Cazin JL
Bull Cancer; 2023 Dec; 110(12):1343-1351. PubMed ID: 37827964
[TBL] [Abstract] [Full Text] [Related]
7. MiRNA-423 rs6505162 and miRNA-6811 rs2292879 SNP associated with lung cancer in Hainan, China.
Zhou J; Meng C; Li Y; Fu Y; Long W; Huang H; Liu Y; Lyu P; Xiao S
Biosci Rep; 2023 Sep; 43(9):. PubMed ID: 37694278
[TBL] [Abstract] [Full Text] [Related]
8. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
Rosenberg JE; Powles T; Sonpavde GP; Loriot Y; Duran I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Mamtani R; Wu C; Matsangou M; Campbell M; Petrylak DP
Ann Oncol; 2023 Nov; 34(11):1047-1054. PubMed ID: 37678672
[TBL] [Abstract] [Full Text] [Related]
9. Impact of Muscle Measures on Outcome in Patients Receiving Endocrine Therapy for Metastatic breast cancer: Analysis of ECOG-ACRIN E2112.
Ballinger TJ; Marques HS; Xue G; Hoffman R; Gatsonis C; Zhao F; Miller KD; Sparano J; Connolly RM
J Natl Compr Canc Netw; 2023 Sep; 21(9):915-923.e1. PubMed ID: 37673107
[TBL] [Abstract] [Full Text] [Related]
10. Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal cancer and Invasive breast cancer.
Cao Y; Efetov SK; He M; Fu Y; Beeraka NM; Zhang J; Zhang X; Bannimath N; Chen K
Arch Immunol Ther Exp (Warsz); 2023 Aug; 71(1):19. PubMed ID: 37566162
[TBL] [Abstract] [Full Text] [Related]
11. Novel models by machine learning to predict prognosis of breast cancer brain metastases.
Li C; Liu M; Zhang Y; Wang Y; Li J; Sun S; Liu X; Wu H; Feng C; Yao P; Jia Y; Zhang Y; Wei X; Wu F; Du C; Zhao X; Zhang S; Qu J
J Transl Med; 2023 Jun; 21(1):404. PubMed ID: 37344847
[TBL] [Abstract] [Full Text] [Related]
12. Comparison of the molecular profiling of core biopsy with surgical specimens in breast cancers and the effect of neoadjuvant therapy on the same - A North Indian study.
Verma P; Sharma N; Gulati A; Sharma R; Parashar A; Kaundal A
J Cancer Res Ther; 2023; 19(2):198-202. PubMed ID: 37313901
[TBL] [Abstract] [Full Text] [Related]
13. [Development and validation of risk prediction model for new-onset cardiovascular diseases among breast cancer patients: Based on regional medical data of Inner Mongolia].
Zhang YJ; Qiao LY; Qi M; Yan Y; Kang WW; Liu GZ; Wang MY; Xi YF; Wang SF
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Jun; 55(3):471-479. PubMed ID: 37291923
[TBL] [Abstract] [Full Text] [Related]
14. Options of locoregional therapy for primary foci of breast cancer influence the rate of nonregional lymph node metastasis in N2-N3 status patients: a SEER database analysis.
Jiao Y; Guo X; Lv Q
Breast Cancer; 2023 Jul; 30(4):647-656. PubMed ID: 37103742
[TBL] [Abstract] [Full Text] [Related]
15. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-breast02): a randomised, open-label, multicentre, phase 3 trial.
André F; Hee Park Y; Kim SB; Takano T; Im SA; Borges G; Lima JP; Aksoy S; Gavila Gregori J; De Laurentiis M; Bianchini G; Roylance R; Miyoshi Y; Armstrong A; Sinha R; Ruiz Borrego M; Lim E; Ettl J; Yerushalmi R; Zagouri F; Duhoux FP; Fehm T; Gambhire D; Cathcart J; Wu C; Chu C; Egorov A; Krop I
Lancet; 2023 May; 401(10390):1773-1785. PubMed ID: 37086745
[TBL] [Abstract] [Full Text] [Related]
16. Pattern of MUC6 expression across 119 different tumor types: A tissue microarray study on 15 412 tumors.
Dwertmann Rico S; Schliesser SJA; Gorbokon N; Dum D; Menz A; Büscheck F; Hinsch A; Lennartz M; von Bargen C; Bawahab AA; Luebke AM; Hube-Magg C; Fraune C; Lebok P; Clauditz TS; Jacobsen F; Sauter G; Uhlig R; Steurer S; Minner S; Marx AH; Simon R; Burandt E; Hoeflmayer D; Krech T; Bernreuther C
Pathol Int; 2023 Jul; 73(7):281-296. PubMed ID: 37057870
[TBL] [Abstract] [Full Text] [Related]
17. Sex-Specific Differences in the Risk of Heart Failure following Anti-HER2 Monoclonal Antibody Therapy.
Suzuki Y; Kaneko H; Tamura Y; Okada A; Michihata N; Jo T; Takeda N; Morita H; Fujiu K; Node K; Yasunaga H; Komuro I
Oncology; 2023; 101(6):358-361. PubMed ID: 36940681
[TBL] [Abstract] [Full Text] [Related]
18. De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early breast cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
Harbeck N; Nitz UA; Christgen M; Kümmel S; Braun M; Schumacher C; Potenberg J; Tio J; Aktas B; Forstbauer H; Grischke EM; Scheffen I; Malter W; von Schumann R; Just M; Zu Eulenburg C; Biehl C; Kolberg-Liedtke C; Deurloo R; de Haas S; Jóźwiak K; Hauptmann M; Kates R; Graeser M; Wuerstlein R; Kreipe HH; Gluz O;
J Clin Oncol; 2023 Aug; 41(22):3796-3804. PubMed ID: 36809046
[TBL] [Abstract] [Full Text] [Related]
19. Trends in Survival and Surgical Methods in Patients Surgically Treated for Metastatic Spinal Tumors: 25-Year Experience in a Single Institution.
Park SJ; Park JS; Lee CS; Kang BJ; Jung CW
Clin Orthop Surg; 2023 Feb; 15(1):109-117. PubMed ID: 36778984
[TBL] [Abstract] [Full Text] [Related]
20. Potential Antihuman Epidermal Growth Factor Receptor 2 Target Therapy Beneficiaries: The Role of MRI-Based Radiomics in Distinguishing Human Epidermal Growth Factor Receptor 2-Low Status of breast cancer.
Bian X; Du S; Yue Z; Gao S; Zhao R; Huang G; Guo L; Peng C; Zhang L
J Magn Reson Imaging; 2023 Nov; 58(5):1603-1614. PubMed ID: 36763035
[TBL] [Abstract] [Full Text] [Related]
[Next]
